Showing promise in the landscape of excess body fat management, retatrutide represents a distinct method. Unlike many current medications, retatrutide operates as a dual agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. The concurrent stimulation encourages several ben